Christoph West­phal finds the ex­it at his lat­est biotech cre­ation — af­ter the stock cratered

High-pro­file Boston biotech fi­nancier Christoph West­phal is leav­ing the helm of his lat­est biotech flop.

A lit­tle more than two years af­ter de­but­ing their IPO with a $16 share price, tiny Flex Phar­ma $FLKS an­nounced that se­r­i­al en­tre­pre­neur West­phal is hand­ing the lead role to R&D chief William McVicar, at least on an in­ter­im ba­sis, and stay­ing on as chair­man.

McVicar was re­cruit­ed to Flex two months ago. Its shares closed Mon­day at $3.43, just a shrunk­en re­flec­tion of its one-time high.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER